TOCAGEN INC (TOCA) Raised to Hold at Zacks Investment Research
TOCAGEN INC (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “
Separately, Stifel Nicolaus reaffirmed a “buy” rating and set a $24.00 price target on shares of TOCAGEN INC in a research report on Tuesday, July 25th.
Shares of TOCAGEN INC (NASDAQ:TOCA) traded down 0.86% during midday trading on Thursday, reaching $12.64. The company had a trading volume of 158,697 shares. The stock’s market capitalization is $250.39 million. TOCAGEN INC has a 52-week low of $9.68 and a 52-week high of $17.95. The company’s 50 day moving average price is $12.27 and its 200 day moving average price is $13.40.
TOCAGEN INC (NASDAQ:TOCA) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.04). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Equities research analysts expect that TOCAGEN INC will post ($2.51) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “TOCAGEN INC (TOCA) Raised to Hold at Zacks Investment Research” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/16/tocagen-inc-toca-raised-to-hold-at-zacks-investment-research-2.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System acquired a new position in TOCAGEN INC during the second quarter worth approximately $179,000. EcoR1 Capital LLC acquired a new position in shares of TOCAGEN INC in the second quarter valued at approximately $18,074,000. State Street Corp acquired a new position in shares of TOCAGEN INC in the second quarter valued at approximately $1,083,000. Goldman Sachs Group Inc. acquired a new position in shares of TOCAGEN INC in the second quarter valued at approximately $366,000. Finally, Farallon Capital Management LLC acquired a new position in shares of TOCAGEN INC in the second quarter valued at approximately $1,203,000. 37.87% of the stock is currently owned by institutional investors.
TOCAGEN INC Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TOCAGEN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TOCAGEN INC and related companies with MarketBeat.com's FREE daily email newsletter.